Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa.

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa.

For the development of human immunodeficiency virus type 1 (HIV-1) vaccines, traditional approaches inducing virus-neutralizing antibodies have so far failed. Thus the effort is now focused on elicitation of cellular immunity. We are currently testing in clinical trials in the United Kingdom and Eas...

Full description

Bibliographic Details
Main Authors:	Nkolola, J, Wee, E, Im, E, Jewell, C, Chen, N, Xu, X, Mcmichael, A, Hanke, T
Format:	Journal article
Language:	English
Published:	2004

Similar Items

Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
by: Im, E, et al.
Published: (2006)

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS.
by: Hanke, T, et al.
Published: (1999)

MVA as a vector for vaccines against HIV-1.
by: Im, E, et al.
Published: (2004)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
by: Wyatt LS, et al.
Published: (2009-10-01)

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime.
by: Hanke, T, et al.
Published: (1998)

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
by: Gilbert, S, et al.
Published: (2006)

Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen
by: Singh V, et al.
Published: (2012-09-01)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
by: Joachim A, et al.
Published: (2012-09-01)

A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.
by: Wee, E, et al.
Published: (2002)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
by: Munseri P, et al.
Published: (2012-09-01)

Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.
by: Hanke, T
Published: (2014)

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.
by: Agricola Joachim, et al.
Published: (2015-01-01)

Development of a DNA-MVA/HIVA vaccine for Kenya.
by: Hanke, T, et al.
Published: (2002)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
by: Podola L, et al.
Published: (2012-09-01)

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
by: Maria L Knudsen, et al.
Published: (2015-01-01)

Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
by: Agricola Joachim, et al.
Published: (2020-11-01)

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.
by: Dunachie, S, et al.
Published: (2006)

Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.
by: Rosamund Chapman, et al.
Published: (2012-01-01)

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
by: Edna O Viegas, et al.
Published: (2018-01-01)

A DNA Prime and MVA Boost Strategy Provides a Robust Immunity against Infectious Bronchitis Virus in Chickens
by: Shaswath S. Chandrasekar, et al.
Published: (2023-01-01)

Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.
by: Sanjay Mehendale, et al.
Published: (2013-01-01)

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
by: Beatriz Perdiguero, et al.
Published: (2018-08-01)

Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
by: Hanke, T, et al.
Published: (2005)

Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.
by: Hanke, T, et al.
Published: (2003)

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use
by: Biberfeldt Gunnel, et al.
Published: (2006-12-01)

HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
by: Tsungai Ivai Jongwe, et al.
Published: (2016-01-01)

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice
by: Georgia Kalodimou, et al.
Published: (2023-05-01)

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees
by: Biberfeld G, et al.
Published: (2009-10-01)

P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice
by: Williamson A, et al.
Published: (2009-10-01)

Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice.
by: Rosamund Chapman, et al.
Published: (2013-01-01)

Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice.
by: Ros Chapman, et al.
Published: (2017-01-01)

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
by: Kimani, D, et al.
Published: (2014)

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques
by: Rosario, M, et al.
Published: (2012)

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.
by: Rosario, M, et al.
Published: (2012)

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
by: Swadling, L, et al.
Published: (2014)

Correction: Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice.
by: Rosamund Chapman, et al.
Published: (2013-01-01)

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.
by: Silvia Ratto-Kim, et al.
Published: (2012-01-01)

Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice
by: Ann-Sophie Stephan, et al.
Published: (2023-01-01)

A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA
by: Ewer (nee Russell), K, et al.
Published: (2016)

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.
by: Patricia J Munseri, et al.
Published: (2015-01-01)